InvestorsHub Logo
Followers 75
Posts 28886
Boards Moderated 2
Alias Born 12/30/2004

Re: ksviking12 post# 263

Thursday, 01/12/2017 11:36:31 AM

Thursday, January 12, 2017 11:36:31 AM

Post# of 672
ksviking12: I hear U. My problem is that I lost more than enough money in VVUS, a start-up pharma, after their flagship drug was approved. Egalet already has revenues and has infrastructure to promote new drugs, though they are going to have to spend more. Maybe this stock would be a deal at $3 and high risk at $6. Super-high risk at $9, my entry point!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.